9 results about "Tracheitis" patented technology

The application discloses application of triacetylandrographolide and a composition thereof in preparation of a medicine for relaxing airway smooth muscle, and belongs to the technical field of medicines. In view of the problems of obvious side effects and narrow treatment window of existing medicines, the application finds that triacetylandrographolide (3, 14, 19-Triacetylandrographolide, TAA) and the composition thereof have tracheal relaxation activity, and the triacetylandrographolide and the composition thereof play a relaxation role through non-competitive antagonism of a downstream signal path of a cholinergic receptor. The new mechanism provides a new idea for developing a new bronchial dilator for overcoming drug resistance of existing medicines. The TAA after preparation optimization can be used for treating or preventing airway obstructive diseases such as asthma, chronic obstructive pulmonary disease, bronchitis and acute lung injury.

Disclosed are compositions and methods for treating, amelioriating, reversing and / or preventing (acting as a prophylaxis): a respiratory condition involving an infection or an inflammation, or any lung condition involving inflammation or infection, e.g., of a respiratory mucosa, and / or an infection or an inflammation of an underlying muscle of the respiratory tract; or, an asthma; a bronchitis; a sinusitis or rhinosinusitis; an infection of a sinus; chronic obstructive airway disease; emphysema; chronic bronchitis; pneumonia; or, a bronchiectasis. In alternative embodiments, the therapeutic combination comprises an orally administered Amphotericin B or equivalent antifungal alone, or a combination of Amphotericin B and: one antibiotic; two antibiotics; three antibiotics; or, four or more antibiotics. In alternative embodiments, these compositions and methods are dosaged and administered to children in need thereof. In alternative embodiments, compositions and methods of the invention are dosaged, formulated and dosaged as tablet, capsule, liquid, powder or aerosol preparations or formulations, or preparations or formulations for oral delivery or inhalation.

The invention relates to the technical field of tracheitis treatment, in particular to a spittoon asthma tablet and a preparation method thereof. The tablets for treating asthma caused by excessive phlegm comprise 60-80 parts of radix sophorae flavescentis extract, 5-10 parts of golden cypress fruit oil, 20-30 parts of filler, 1-2 parts of lubricant, 5-10 parts of lily, 2-5 parts of fried almond and 0.5-1 part of liquorice. The sophora flavescens extract, the cortex phellodendri oil and the lily have a synergistic effect, and after the sophora flavescens extract, the cortex phellodendri oil and the lily are combined, cough and asthma such as chronic tracheitis or bronchitis can be remarkably treated, and the effect is remarkable.

The invention belongs to the field of biological medicine, and particularly relates to application of small molecules in prevention and treatment of acute and chronic bronchitis, N-dodecyl methylamine can significantly prolong cough latency time of mice suffering from acute or chronic bronchitis, significantly reduce cough times of the mice suffering from acute or chronic bronchitis, and significantly improve cough latency time of the mice suffering from acute or chronic bronchitis. The micromolecule can be used as a medicine for treating or relieving acute or chronic bronchitis, and a new choice is provided for clinical treatment of bronchitis; double distilled water suspension small molecules are adopted for administration, the method is simple, convenient and rapid, and a remarkable effect is achieved. The micromolecule can obviously reduce the cough frequency and cough latency time of acute and chronic bronchitis, and has a good clinical application prospect.

The invention discloses a human-derived anti-respiratory syncytial virus neutralizing antibody RS414 and application of the human-derived anti-respiratory syncytial virus neutralizing antibody RS414. The antibody RS414 is obtained by screening by using a phage surface presentation technology. The antibody specifically recognizes the respiratory syncytial virus particle antigen, aims at the F protein of the respiratory syncytial virus, has obvious enzyme-linked immunosorbent assay reaction with the respiratory syncytial virus, and has a neutralizing activity function of resisting respiratory syncytial virus infection. The antibody provided by the invention can be prepared into a specific antibody drug for preventing and treating respiratory syncytial virus infection, and can be used for clinically preventing or treating lower respiratory tract infection, especially severe lower respiratory tract infection (pneumonia and capillary bronchitis) caused by the respiratory syncytial virus.

The application optimizes the antigen component of the bovine contagious nasal tracheitis inactivated vaccine, and prepares a new bovine contagious nasal tracheitis inactivated vaccine, which can produce high level of neutralizing antibody after immunizing the bovine; the safety of the vaccine is improved through the suspension culture process promotion and the inactivation agent, adjuvant screening and purification process promotion. The safety and efficacy test results show that: after the bovine is immunized by using the inactivated vaccine, no adverse reaction is produced, and high level of neutralizing antibody is produced. The results show that the immunization effect of the bovine contagious nasal tracheitis inactivated vaccine can be improved by using the application.

This invention relates to a one-tube colorimetric LAMP primer composition, kit, and applications for detecting feline infectious rhinotracheitis virus (FLVR), belonging to the field of molecular biology technology. It solves the problems of existing PCR and qPCR-based infectious disease detection methods, which require complex and expensive temperature control equipment, demand highly skilled operators, have long detection times, and are unsuitable for on-site point-of-care testing. The primer composition of this invention includes an outer primer, an inner primer, and a loop primer. The outer primer consists of an upstream primer F3 and a downstream primer B3; the inner primer consists of an upstream primer FIP and a downstream primer BIP; and the loop primer consists of an upstream primer LF and a downstream primer LB, with sequences shown in SEQ ID NO. 1-6, respectively. This primer composition provides rapid detection, high specificity, a detection limit comparable to qPCR, excellent repeatability and stability, requires no specialized equipment, allows for visual result interpretation, and is suitable for on-site point-of-care testing.

To provide a method for treating bronchiolitis in infants.SOLUTION: The method comprising repeatedly administering to the infant a gas mixture comprising nitric oxide in a concentration of about 144 to about 176ppm for a first period of time, followed by a gas mixture that does not include nitric oxide for a second period of time; The administration is repeated for a time sufficient to a) reduce the length of hospitalization required to achieve 92% or greater oxygen saturation in room air, b) reduce the length of hospitalization required to achieve a clinical score of 5 or less, c) reduce the length of hospitalization required to discharge from hospital, or d) any combination thereof, as compared to an infant not subjected to the repeated administration of nitric oxide.SELECTED DRAWING: Figure 1

Provided in the present invention are an anti-RSV antibody and the use of the anti-RSV antibody in the preparation of a drug for preventing or treating RSV infections or symptoms or diseases related thereto, wherein the RSV infections comprise subtype A and subtype B infections and upper respiratory tract RSV infections and / or lower respiratory tract RSV infections, and the symptoms or diseases related to RSV infections comprise fevers, coughs, sore throats, runny noses, and dyspnea, bronchitis or pneumonia caused by RSV infections.